Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2026-05-28 Audit Report / Informat…
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
The Board of Directors of the comoany at the meeting held on Wednesday, May 27, 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each ....
Audit Report / Information Classification · 85% confidence The document is an official stock‐exchange filing under SEBI Listing Regulations disclosing the audited consolidated and standalone financial results for the year ended March 31, 2026, and it attaches the full Independent Auditor’s Report with unmodified opinion. It is not a full Annual Report (10-K), nor a brief earnings summary (ER), nor a quarterly/interim report (IR) for a sub-year period. It contains the standalone audit report itself, which matches the definition of AR: a standalone audit report (excluding full annual reports). FY 2026
2026-05-28 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 76% confidence The document is a compliance disclosure submitted to BSE and NSE under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides a Statement of Deviation(s) or Variation(s) in utilization of funds raised through a preferential issue for the quarter and year ended March 31, 2026. This is a regulatory announcement rather than an original financial report, earnings release, or capital-raising proposal. It does not contain substantive financial statements or an investor presentation but fulfills a listing compliance obligation. Therefore, it falls into the general Regulatory Filings category (RNS).
2026-05-28 English
Statement of Deviation & Variation Report - March 31, 2026
Regulatory Filings Classification · 85% confidence The document is a compliance submission under SEBI Listing Regulations (Regulation 32) providing a Statement of Deviation/Variation in use of funds raised through a preferential issue. It is not a full financial report (e.g., Annual Report, Interim Report) nor an earnings announcement. It is a routine regulatory filing to stock exchanges, with no substantive financial statements, but a statutorily mandated disclosure. Thus it falls under the general Regulatory Filings (RNS) category.
2026-05-28 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 88% confidence The document is a stock exchange filing notifying the publication of the company’s audited financial results for the quarter and year ended March 31, 2026 by way of newspaper advertisement. It does not contain the full financial statements itself but merely encloses an extract of the published results and directs readers to the website. This is a report publication announcement rather than the report itself.
2026-05-28 English
Announcement under Regulation 30 (LODR) - Newspaper Publication for BM held on 27.05.2026
Earnings Release Classification · 85% confidence The document is a mandated regulatory submission under SEBI LODR that encloses the newspaper advertisement (extract) of the company’s audited financial results for the quarter and full year ended March 31, 2026. It is not the full Annual Report or a detailed interim report, but rather the initial public disclosure of audited quarterly/year‐end results (key extracts) via newspaper advertisement. As such, it best fits the “Earnings Release” category. FY 2026
2026-05-28 English
Outcome of Board Meeting
Earnings Release Classification · 78% confidence The document is a formal ‘Outcome of Board Meeting’ notice filed under SEBI Listing Regulations announcing the audited quarterly and full‐year financial results and including the Independent Auditor’s Report. It is not the full Annual Report (10‐K) or a separate Interim Report (IR) and is more than a simple report publication notice (RPA). It constitutes the initial public disclosure of the period’s financial results and auditors’ opinions, matching the definition of an Earnings Release (ER). FY 2026
2026-05-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.